Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience

[1]  T. Wong,et al.  Systemic Factors Associated with Treatment Response in Diabetic Macular Edema , 2020, Journal of ophthalmology.

[2]  J. Chhablani,et al.  Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity , 2020, Acta ophthalmologica.

[3]  C. Creuzot-Garcher,et al.  Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry. , 2019, Ophthalmology.

[4]  Daniel L. Chao,et al.  OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema. , 2019, Ophthalmology. Retina.

[5]  A. Ambrósio,et al.  Evaluation of markers of outcome in real-world treatment of diabetic macular edema , 2018, Eye and Vision.

[6]  N. Bressler,et al.  Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial , 2018, JAMA ophthalmology.

[7]  A. Bruynseels,et al.  Effect of glycosylated hemoglobin on response to ranibizumab therapy in diabetic macular edema: real-world outcomes in 312 patients. , 2017, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[8]  J. Cunha-Vaz,et al.  OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study , 2017, Retina.

[9]  P. Kaiser,et al.  Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. , 2016, Ophthalmology.

[10]  Rishi P. Singh,et al.  The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema. , 2016, Ophthalmology.

[11]  F. Wolf,et al.  Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers , 2016, Clinical Diabetes.

[12]  Sherri A Van Everen,et al.  Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema: A Post Hoc Analysis of the RIDE/RISE Trials. , 2015, Ophthalmology.

[13]  H. Hammes,et al.  Risk Factors for Retinopathy and DME in Type 2 Diabetes—Results from the German/Austrian DPV Database , 2015, PloS one.

[14]  P. Campochiaro,et al.  Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab. , 2015, Ophthalmology.

[15]  N. Bressler,et al.  Prevalence of and risk factors for diabetic macular edema in the United States. , 2014, JAMA ophthalmology.

[16]  P. Kaiser,et al.  Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.

[17]  Rishi P. Singh,et al.  The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. , 2014, Journal of diabetes and its complications.

[18]  P. Romero-Aroca,et al.  Laser Treatment for Diabetic Macular Edema in the 21st Century , 2014, Current diabetes reviews.

[19]  Massimo Porta,et al.  Medical management for the prevention and treatment of diabetic macular edema. , 2013, Survey of ophthalmology.

[20]  N. Koo,et al.  Relationship between the Morphology of Diabetic Macular Edema and Renal Dysfunction in Diabetes , 2013, Korean journal of ophthalmology : KJO.

[21]  M. Mahgoub,et al.  The Effect of Glycemic Control on Visual and Anatomic Outcomes in Response to Therapy for Diabetic Macular Edema , 2013, European journal of ophthalmology.

[22]  Quan Dong Nguyen,et al.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. , 2012, Ophthalmology.

[23]  B. Klein,et al.  Global Prevalence and Major Risk Factors of Diabetic Retinopathy , 2012, Diabetes Care.

[24]  Josef Coresh,et al.  Chronic kidney disease , 2012, The Lancet.

[25]  Chih-jen Wu,et al.  Difference between CKD-EPI and MDRD equations in calculating glomerular filtration rate in patients with cirrhosis. , 2011, World journal of gastroenterology.

[26]  S. Okudan,et al.  Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema. , 2011, Journal of diabetes and its complications.

[27]  Francesco Bandello,et al.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.

[28]  Simon P. Harding,et al.  Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study) , 2010, Diabetes Care.

[29]  M. Elshafie,et al.  Pretreatment clinical variables associated with the response to intravitreal bevacizumab (Avastin) injection in patients with persistent diabetic macular edema. , 2010, Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society.

[30]  Quan Dong Nguyen,et al.  Persistent diabetic macular edema is associated with elevated hemoglobin A1c. , 2005, American journal of ophthalmology.

[31]  T. Bek,et al.  Macular edema reflects generalized vascular hyperpermeability in type 2 diabetic patients with retinopathy. , 2002, Diabetes care.

[32]  F. Akay,et al.  Diabetic Macular Edema , 1969, Pakistan journal of medical sciences.

[33]  R. Meirelles,et al.  Use of Optical Coherence Tomography (OCT) and Indirect Ophthalmoscopy in the Diagnosis of Macular Edema in Diabetic Patients , 2004, International Ophthalmology.

[34]  D. del Castillo,et al.  [Prospective study of correlation between diabetic retinopathy and microalbuminuria in diabetes type 1 patients]. , 2000, Archivos de la Sociedad Espanola de Oftalmologia.

[35]  R. Klein,et al.  The 14-year incidence of visual loss in a diabetic population. , 1998, Ophthalmology.